HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Type II Tumor Necrosis Factor Receptors

Subscribe to New Research on Type II Tumor Necrosis Factor Receptors

A tumor necrosis factor receptor subtype that is expressed primarily in IMMUNE SYSTEM cells. It has specificity for membrane-bound form of TUMOR NECROSIS FACTORS and mediates intracellular-signaling through TNF RECEPTOR ASSOCIATED FACTORS.

Also Known As:

Receptors, Tumor Necrosis Factor, Type II; CD 120b Antigen; CD120b Antigen; TNF-R2; TNF-R75; TNF-RII; TNF-sR75; TNFR p75; TNFR p80; TNFR2; TNFRSF1B Receptor; Tumor Necrosis Factor Receptor 2; Tumor Necrosis Factor Receptor 75; Tumor Necrosis Factor Receptor Type 2; 120b Antigen, CD; Antigen, CD 120b; Antigen, CD120b; Receptor, TNFRSF1B; Antigens, CD120b; CD120b Antigens; Receptors, Tumor Necrosis Factor, Member 1B; Tumor Necrosis Factor Receptor Superfamily, Member 1B; Tumor Necrosis Factor Receptor Type II

Networked: 456 relevant articles (18 outcomes, 60 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Tokunaga, K: 7 articles (10/2001 - 04/2000)
2.	Chen, Xin: 6 articles (11/2015 - 05/2008)
3.	Min, Wang: 6 articles (09/2013 - 09/2006)
4.	Oppenheim, Joost J: 5 articles (06/2014 - 05/2008)
5.	Mayadas, Tanya N: 5 articles (05/2013 - 05/2005)
6.	Niewczas, Monika A: 4 articles (04/2015 - 03/2012)
7.	Krolewski, Andrzej S: 4 articles (04/2015 - 03/2012)
8.	Kamada, Haruhiko: 4 articles (02/2015 - 03/2009)
9.	Mukai, Yohei: 4 articles (02/2015 - 03/2009)
10.	Tsutsumi, Yasuo: 4 articles (02/2015 - 03/2009)

Related Diseases

1.	Infection 10/15/2001 - "By contrast, HHV-7 infection caused a marked decrease of surface TRAIL-R1, but not of TRAIL-R2, CD95, TNF-R1, or TNF-R2. " 09/01/2000 - "Lung macrophages from both groups of knockout mice released substantial amounts of NO. Upon secondary infection, TNFR2-/- mice survived rechallenge and cleared infection as efficiently as C57BL/6 animals. " 09/01/2015 - "Taken together, this study identifies critical cellular mechanisms regulating TNFR2 shedding on CD8(+) T cells and demonstrates that TNFR2 contributes, in part, to the regulation of TNF-α levels during infection. " 01/01/2013 - "Further study is needed to determine whether these mutations found in the regulatory region influence TNF-RII gene expression, modulate the body's immune response and susceptibility to infections." 09/01/2015 - "Our findings imply that variations in the genes governing the levels of constitutive and inducible TNF-α and TNF RII might be an important risk factor, which could explain the variable outcomes of HBV infection. "
2.	Inflammation 01/01/2008 - "If inactivation of TNF-dependent inflammation in the brain is warranted by additional pre-clinical studies, selective targeting of TNFR1-mediated signaling while sparing TNFR2 activation may lessen adverse effects of anti-TNF therapies in the CNS." 01/01/2015 - "Alteration in the frequency of Tregs and Tregs expressing CD62L or TNFR2 in type 1 diabetes is associated with increased inflammation, poor glycemic control and risk of micro-vascular complications." 01/01/2015 - "Regulatory T cells with CD62L or TNFR2 expression in young type 1 diabetic patients: relation to inflammation, glycemic control and micro-vascular complications." 05/01/2014 - "Tnfa signaling through tnfr2 protects skin against oxidative stress-induced inflammation." 01/01/2013 - "Previously described TNFR2-dependent glomerular inflammation may therefore require TNFR2 activation by membrane-bound, but not soluble TNF. "
3.	Demyelinating Diseases (Demyelinating Disease) 11/15/2015 - "Overall, TNFR2 blockade appears to disrupt commensal bacteria-host immune symbiosis to reveal autoimmune demyelination in genetically susceptible mice. " 02/01/1999 - "In contrast, the course of EAE in TNFR2-/- mice was severe and associated with remarkable demyelination. " 05/01/2011 - "Insomuch as TNFR1 mediates demyelination and TNFR2 remyelination, it could be hypothesized that anti-TNF-α agents which selectively inhibit sTNF or signals from TNFR1 could be effective in treating MS." 11/15/2015 - "We demonstrate that TNFR2 deficiency results in female-biased spontaneous autoimmune CNS demyelination in myelin oligodendrocyte glycoprotein-specific 2D2 TCR transgenic mice. " 12/15/2009 - "CONCLUSION.: Our results suggested that the proportion of apoptotic oligodendrocytes, causing spongy axonal degeneration and demyelination, correlated with the magnitude of cord compression and that overexpression of TNF-alpha, TNFR1, and TNFR2 seems to participate in apoptosis of such cells in the chronically compressed spinal cord."
4.	Neoplasms (Cancer) 11/15/2009 - "The enhanced protection against tumor cell growth was not due to more effective activation of OVA-specific memory CD8 T cells in vaccinated TNFR2(-/-) mice. " 11/15/2009 - "Furthermore, vaccination of TNFR2(-/-) mice with recombinant Listeria monocytogenes that express OVA confers better protection against the growth of OVA-expressing E.G7 tumor cells relative to similarly vaccinated WT mice. " 11/15/2009 - "We determined whether the resistance of activated TNFR2(-/-) CD8 T cells to AICD contributes to more effective protection against tumor cell growth. " 11/15/2009 - "Thus, the enhanced protection against E.G7 in TNFR2(-/-) mice is likely due to the recruitment and activation of OVA-specific memory TNFR2(-/-) CD8 T cells and their prolonged survival at the tumor site." 05/15/2008 - "In this study, we characterized the phenotype and function of TNFR2(+) Tregs in peripheral lymphoid tissues of normal and tumor-bearing C57BL/6 mice. "
5.	Sepsis (Septicemia) 07/01/2002 - "We analyzed the value of prospectively measuring serum concentrations of soluble tumor necrosis factor receptor type II (sTNF-RII) in patients with AML for early diagnosis of sepsis in neutropenia. " 04/01/2005 - "These data suggest that in sepsis, TNFR1 mediates much of the TNF-alpha-induced pathology, whereas TNFR2 mediates protective effects." 04/01/2005 - "Tumor necrosis factor (TNF)-alpha, a cardinal molecule in the cascade of sepsis-induced host injury, binds to two distinct receptors: tumor necrosis factor receptor (TNFR) 1 and TNFR2. " 01/01/2009 - "43 patients with MPO-ANCA-associated vasculitis, 16 patients with chronic renal failure, 10 patients with sepsis, 15 patients with systemic lupus erythematosus, and 18 healthy controls were enrolled in this study, and the surface expression levels of TNFR1, TNFR2, CD63, and CD64 on granulocytes were assessed. "

Related Drugs and Biologics

1.	Type I Tumor Necrosis Factor Receptors
2.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
3.	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)
4.	NF-kappa B (NF-kB)
5.	infliximab (Remicade)
6.	Proteins (Proteins, Gene)
7.	Interferons
8.	Interleukin-18 (Interleukin 18)
9.	Type II Tumor Necrosis Factor Receptors
10.	HLA-DRB1 antigen (HLA DRB1)

Related Therapies and Procedures

1.	Moxibustion
2.	Injections
3.	Renal Replacement Therapy (Therapies, Renal Replacement)
4.	Gastric Bypass (Roux-en-Y Gastric Bypass)
5.	Homologous Transplantation (Allograft)